Most of these mutations are missense point mutations that target the DNA-binding core domain (DBD) [8], thereby abolishing specific DNA binding of p53, preventing p53-dependent transcription, and abrogating p53-mediated tumor suppression. The gene discussed is TP53; the disease is neoplasm.